HENDERSON, Nev. / Aug 29, 2023 / Business Wire / P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, announces that it will participate at the upcoming Wells Fargo Healthcare Conference in Boston, Massachusetts.
Management will give a presentation on Thursday, September 7th, 2023, at 4:30 PM Eastern Time. A webcast of the live event will be available on the P3 Investor Relations website at ir.p3hp.org. A replay will be available shortly after the live event.
About P3 Health Partners (NASDAQ: PIII)
P3 Health Partners Inc. is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, P3 has an expansive network of more than 2,600 affiliated primary care providers across the country. Our local teams of health care professionals manage the care of thousands of patients in 18 counties across five states. P3 supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the P3 care team creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. For more information, visit www.p3hp.org and follow us on LinkedIn and at Facebook.com/p3healthpartners.
| Last Trade: | US$3.60 |
| Daily Change: | -0.01 -0.28 |
| Daily Volume: | 2,324 |
| Market Cap: | US$11.770M |
December 02, 2025 November 24, 2025 November 13, 2025 August 25, 2025 August 14, 2025 | |

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load